Modular analytics cobas 6000 analyzer

The following clinical characteristics were collected via face-to-face interviews: age, sex, smoking status, alcohol drinking status, education, and histories of hypertension and diabetes. Height was measured to the nearest 0.5 cm and weight was measured to the nearest 0.1 kg using an automatic device (Ultrasonic body scale; SONKA Inc., Shenzhen, China). Body mass index (BMI) was calculated as weight/height² (kg/m²).
Blood samples were obtained from the antecubital vein of each participant during the morning after ≥ 8 h of fasting. Serum concentrations of uric acid, Cr, CysC, creatine kinase (CK), and albumin were detected using the Cobas c702 chemistry autoanalyzer (Roche Diagnostics, Switzerland). Serum C-reactive protein (CRP) concentrations were detected using an immunoturbidimetric technique with the Modular Analytics Cobas 6000 analyzer (Roche Diagnostics, Switzerland). Hemoglobin concentrations were detected using a Sysmex XE-500 analyzer (Sysmex Corporation, Japan). The Cr/CysC ratio was calculated as Cr/CysC ratio = serum Cr (mg/dL)/serum CysC (mg/L) × 10.

Serum samples were collected at 6 am after fasting at night (at least 8 h). Cobas c702 chemistry autoanalyzer (Roche Diagnostics, Switzerland) methods were used to measure serum lipid metabolism indicators, including high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG); glucose metabolism indicators, including (FBG) fasting blood glucose, (HbA1c) glycosylated hemoglobin; Bone metabolism indicators, including β-CTX, PINP, 25-hydroxy-vitamin (25(OH)D) and parathyroid hormone (PTH); other laboratory markers such as creatinine, calcium, uric and albumin. Serum cystatin C concentrations were detected using an immunoturbidimetric technique with the Modular Analytics Cobas 6000 analyzer (Roche Diagnostics, Switzerland). The CCR was then calculated as the serum creatine concentration (mg/L) divided by the cystatin C concentration (mg/L).